Breaking News
Sort by:
Top Post
Roche’s Tecentriq Plus Avastin Reduced Risk of Cancer Returning in People with Certain Types of Adjuvant Liver Cancer in a Phase III Study
Roche has announced new data from the Phase III IMbrave050 study that show Tecentriq (atezolizumab) […]
Lunit Meets MDR CE Requirements for 3D Breast Tomosynthesis AI Solution
Lunit, a leading global provider of AI-powered cancer solutions, today announced that its AI solution […]
China's First Personalized Neoantigen-Targeted Cancer Vaccine Receives NMPA's Clinical Trial Approval
According to the latest data released in the Clinical Trials Implied Approval section on the […]
Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer
Pfizer and Astellas Pharma have announced positive topline results from the Phase 3 EMBARK trial […]
Invitae Appoints Dr. W. Michael Korn as Chief Medical Officer for Oncology
Invitae, a leading medical genetics company, has announced the appointment of Dr. W. Michael Korn, […]
Propanc Biopharma Confirms PRP Exerts Significant Effects Against Chemoresistant Pancreatic Tumor Cells
Propanc Biopharma, a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and […]
Syndax Pharmaceuticals Announces Two Publications in Nature of Data from the Phase 1 Portion of AUGMENT-101 in Acute Leukemia Patients
Syndax Pharmaceuticals, today announced that data from the Phase 1 portion of the ongoing Phase […]
DEM BioPharma Appoints Miriam Merad, M.D., Ph.D., to Scientific Advisory Board
DEM BioPharma, an immune-oncology company developing therapies that target signals on cancer cells and macrophages […]
Catamaran Bio Selects OmniaBio as Partner to Develop and Manufacture Allogeneic CAR-NK Cell Therapies
Catamaran Bio, a biotechnology company developing off-the-shelf NK cell therapies to treat cancer, and OmniaBio, […]
Cantargia Treats First Triple-Negative Breast Cancer Patient in Randomized Phase II Part of TRIFOUR Trial
Cantargia today reported that, following positive results in the lead-in phase of the clinical phase […]
Telix's ZIRCON Phase III Kidney Cancer Imaging Study Presented in "Game Changing" Session at EAU
Telix Pharmaceuticals today announces additional positive results from its completed pivotal Phase III ZIRCON study […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more